BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

Rheumatology (Oxford). 2010 Nov;49(11):2217-9. doi: 10.1093/rheumatology/keq249a. Epub 2010 Sep 12.

Authors

Tina Ding¹, Jo Ledingham, Raashid Luqmani, Sarah Westlake, Kimme Hyrich, Mark Lunt, Patrick Kiely, Marwan Bukhari, Rikki Abernethy, Ailsa Bosworth, Andrew Ostor, Kate Gadsby, Frank McKenna, Diana Finney, Josh Dixey, Chris Deighton; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR

Affiliation

¹ Rheumatology Department, Royal Derby Hospital, Derby, UK. tina.ding@doctors.net.uk

PMID: 20837498
DOI: 10.1093/rheumatology/keq249a

No abstract available

MeSH terms

Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Drug Monitoring / methods
Humans
Immunosuppressive Agents / adverse effects*
Patient Selection
Practice Guidelines as Topic*
Tumor Necrosis Factor-alpha / adverse effects
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
United Kingdom

Substances

Antirheumatic Agents
Immunosuppressive Agents
Tumor Necrosis Factor-alpha